[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU5528299A - Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s) - Google Patents

Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s)

Info

Publication number
AU5528299A
AU5528299A AU55282/99A AU5528299A AU5528299A AU 5528299 A AU5528299 A AU 5528299A AU 55282/99 A AU55282/99 A AU 55282/99A AU 5528299 A AU5528299 A AU 5528299A AU 5528299 A AU5528299 A AU 5528299A
Authority
AU
Australia
Prior art keywords
inflammation
treatment
antibacterial agent
combined therapy
elastase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55282/99A
Inventor
Samarendra N Maiti
Ronald G. Micetich
O. A. Phillips
Sameeh Salama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naeja Pharmaceutical Inc
Original Assignee
Naeja Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naeja Pharmaceutical Inc filed Critical Naeja Pharmaceutical Inc
Publication of AU5528299A publication Critical patent/AU5528299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU55282/99A 1998-09-15 1999-09-15 Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s) Abandoned AU5528299A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10038698P 1998-09-15 1998-09-15
US60100386 1998-09-15
PCT/IB1999/001547 WO2000015207A2 (en) 1998-09-15 1999-09-15 Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)

Publications (1)

Publication Number Publication Date
AU5528299A true AU5528299A (en) 2000-04-03

Family

ID=22279479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55282/99A Abandoned AU5528299A (en) 1998-09-15 1999-09-15 Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s)

Country Status (2)

Country Link
AU (1) AU5528299A (en)
WO (1) WO2000015207A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2728301A (en) * 2000-01-06 2001-07-16 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
US6552082B2 (en) 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
WO2002064089A2 (en) * 2001-02-13 2002-08-22 Intrabiotics Pharmaceuticals, Inc. Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial ib-367 peptides
RU2373937C9 (en) * 2003-02-10 2010-07-27 Байер Шеринг Фарма Акциенгезельшафт Therapy of respiratory apparatus bacteriosis by local application of fluoroquinolones
DE10350409A1 (en) * 2003-10-28 2005-05-25 Bayer Healthcare Ag Method employing quinolones and related substances for treatment and prophylaxis of genetic diseases causing local mutations and comparable defects in higher organisms, including human beings
CN108570418A (en) * 2018-04-08 2018-09-25 山东农业大学 A kind of aspergillus fumigatus agar beads and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564317A (en) * 1976-06-25 1980-04-10 Roche Products Ltd Dipeptide derivatives
IL69795A (en) * 1983-09-23 1987-01-30 Univ Ramot Ophthalmic preparations containing as active ingredient 2-mercaptoalkanoyl peptides
US5439904A (en) * 1993-12-07 1995-08-08 Synphar Laboratories, Inc. 2-spiro(2'-spirocycloalkyl)cyclopropyl cephalosporin sulfones as antiinflammatory and antigenerative agents

Also Published As

Publication number Publication date
WO2000015207A2 (en) 2000-03-23
WO2000015207A3 (en) 2000-05-25
WO2000015207B1 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
AU2197100A (en) Treatment of tooth surfaces and substance therefor
AU5468599A (en) Intra-luminal device for treatment of body cavities and lumens and method of use
AU6030799A (en) Treatment of wound or joint for relief of pain and promotion of healing
AU7622198A (en) Methods of treating mental diseases, inflammation and pain
AU6411199A (en) Angiogenically effective unit dose of fgf and method of administering
AUPQ877300A0 (en) Topical treatment of skin
AU9016898A (en) Methods and compositions for treatment of restenosis
AU8011194A (en) Compounds, compositions and treatment of allergies and inflammation
AU7957894A (en) Compounds, compositions and treatment of allergies and inflammation therewith
AU1331399A (en) Preparation for prevention and healing of inflammation affections
AU3119199A (en) Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
AU5056099A (en) Compounds for use in the treatment of inflammation
AUPQ201499A0 (en) Treatment of inflammatory and malignant diseases
AU5528299A (en) Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s)
AUPQ344799A0 (en) Treatment of respiratory diseases and infections
AU4261399A (en) Use of crataegus formulations for prophylaxis and treatment of neoplastic diseases
AU3607597A (en) Pharmaceutical composition for prophylaxis and/or treatment of apoptosis-related diseases
AU1293400A (en) Enzymatic treatment and prevention of hypertrophic skin
AU3760900A (en) Treatment of menstrual function
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
AU1853397A (en) Treatment of pulmonary inflammation
AU2001292818A1 (en) Use of transcription factors for treating inflammation and other diseases
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2001267177A1 (en) Diagnosis and treatment of herpes infections
AU2380097A (en) Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase